Allergic rhinitis; Asthma; EQ-5D-5L; Health-related quality of life; Mobile health; Quality of life; Real-world data; Utilities; Humans; Male; Female; Adult; Cross-Sectional Studies; Middle Aged; Young Adult; Adolescent; Surveys and Questionnaires; Aged; Europe/epidemiology; Quality of Life; Asthma/epidemiology; Rhinitis, Allergic/epidemiology; Europe; Rhinitis, Allergic; Immunology and Allergy
Abstract :
[en] [en] BACKGROUND: Allergic rhinitis (AR) and asthma may affect health-related quality of life. However, national estimates on the quality of life of patients with AR or asthma are lacking.
OBJECTIVE: To provide estimates for utility scores and EuroQoL five-dimension (EQ-5D) visual analog scale (VAS) for patients with AR or asthma.
METHODS: We conducted a cross-sectional study using direct patient data from the MASK-air app on European MASK-air users with self-reported AR or asthma. We used a multi-attribute instrument (EQ-5D) to measure quality of life (as utility scores and EQ-5D VAS values). Mean scores were calculated per country and disease control level using multilevel regression models with poststratification, accounting for age and sex biases.
RESULTS: We assessed data from 7905 MASK-air users reporting a total of up to 82,737 days. For AR, utilities ranged from 0.86 to 0.99 for good control versus 0.72 to 0.85 for poor control; EQ-5D VAS levels ranged from 78.9 to 87.9 for good control versus 55.3 to 64.2 for poor control. For asthma, utilities ranged from 0.84 to 0.97 for good control versus 0.73 to 0.87 for poor control; EQ-5D VAS levels ranged from 68.4 to 81.5 for good control versus 51.4 to 64.2 for poor control. Poor disease control was associated with a mean loss of 0.14 utilities for both AR and asthma. For the same control levels, AR and asthma were associated with similar utilities and EQ-5D VAS levels. However, lower values were observed for asthma plus AR compared with AR alone.
CONCLUSIONS: Poor AR or asthma control are associated with reduced quality of life. The estimates obtained from mobile health data may provide valuable insights for health technology assessment studies.
Disciplines :
Cardiovascular & respiratory systems
Author, co-author :
Vieira, Rafael José; Department of Community Medicine, Information, and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal
Leemann, Lucas; Department of Political Science, University of Zurich, Zurich, Switzerland
Briggs, Andrew; Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, United Kingdom
Pereira, Ana Margarida; Department of Community Medicine, Information, and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal
Savouré, Marine; Inserm, Equipe d'Epidémiologie Respiratoire Intégrative, CESP, Villejuif, France, Université Paris-Saclay, Université de Versailles Saint-Quentin-en-Yvelines, Université Paris-Sud, Villejuif, France
Kuna, Piotr; Division of Internal Medicine, Asthma, and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland
Morais-Almeida, Mário; Allergy Center, CUF Descobertas Hospital, Lisbon, Portugal
Bewick, Michael; University of Central Lancashire Medical School, Preston, United Kingdom
Azevedo, Luís Filipe; Department of Community Medicine, Information, and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal
Louis, Renaud ; Université de Liège - ULiège > Département des sciences cliniques > Pneumologie - Allergologie
Klimek, Ludger; Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany, Center for Rhinology and Allergology, Wiesbaden, Germany
Bahbah, Farah; Stallergenes Greer, Ltd, Antony, France
Samolinski, Boleslaw; Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland
Anto, Josep M; ISGlobal, Barcelona Institute for Global Health, Barcelona, Spain, Universitat Pompeu Fabra, Barcelona, Spain, CIBER Epidemiología y Salud Pública, Barcelona, Spain
Zuberbier, Torsten; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany
Fonseca, João A; Department of Community Medicine, Information, and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal
Bousquet, Jean; Institute of Allergology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology, Berlin, Germany, MASK-air SAS, Montpellier, France. Electronic address: jean.bousquet@orange.fr
Sousa-Pinto, Bernardo; Department of Community Medicine, Information, and Health Decision Sciences, Faculty of Medicine, University of Porto, Porto, Portugal, Centre for Health Technology and Services Research, Health Research Network (CINTESIS@RISE), Faculty of Medicine, University of Porto, Porto, Portugal
This work was supported by PhD Grant Reference 2022.12787.BD, funded by Portuguese national funds and community funds from the European Social Fund and Programa Por_Norte through Funda\u00E7\u00E3o para a Ci\u00EAncia e a Tecnologia (FCT-MCTES, Portugal). The funder had no role in (1) the design and conduct of the study; (2) the collection, management, analysis, and interpretation of the data; (3) the preparation, review, or approval of the manuscript; and (4) the decision to submit the manuscript for publication.Conflicts of interest: J. Bousquet reports personal fees from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi-Aventis, Teva, and Uriach; and other from KYomed-Innov and Mask-air-SAS, outside the submitted work. R. Louis reports grants and personal fees from GSK and AstraZeneca and grants from Chiesi, outside the submitted work. P. Kuna reports personal fees from Adamed, Berlin Chemie Menarini, Boehringer Ingelheim, Celon Pharma, FAES, Glenmark, Novartis, GSK, Sanofi, Teva, and Polpharma; and personal fees and other from AstraZeneca, outside the submitted work. A. Briggs reports personal fees from Alexion, ALK, Amgen, AstraZeneca, BMS, Daiichi-Sankyo, Gilead, GSK, Idorsia, MSD, Pfizer, Rhythm, and Takeda, outside the submitted work. T. Zuberbier reports grants and personal fees from Novartis and Henkel; and personal fees from Bayer, FAES, AstraZeneca, AbbVie, ALK, Almirall, Astellas, Bencard, Berlin Chemie, Hal, Leti, Mesa, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes, Takeda, Teva, UCB, Henkel, Kryolan, and L'Or\u00E9al, outside the submitted work; is a committee member of World Health Organization Initiative \"Allergic Rhinitis and Its Impact on Asthma,\" a member of the board for the German Society for Allergy and Clinical Immunology, head of the European Centre for Allergy Research Foundation , president of the Global Allergy and Asthma European Network , and a member of the Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization . L. Klimek reports grants and personal fees from Allergopharma, Viatris, LETI Pharma, Stallergenes, GSK, and Sanofi; grants from Quintiles, ASIT Biotech, Lofarma, AstraZeneca, and Inmunotek; and personal fees from Allergy Therapeut, Cassella Med, ALK Abell\u00F3, HAL Allergie, Novartis, Regeneron Pharmaceuticals, and ROXALL Medizin GmbH , outside the submitted work; and is a member of the German Society for Applied Allergology, the German Society of Otorhinolaryngology, Head and Neck Surgery , Deutsche Akademie f\u00FCr Allergologie und klinische Immunologie, the German Association of Ear, Nose, Throat, and Neck Surgeons, the Society for Pediatric Allergy and Environmental Medicine, and the European Academy of Allergy and Clinical Immunology. The rest of the authors declare that they have no relevant conflicts of interest.This work has been made possible owing to a partnership among researchers (L. Leemann, J.M. Anto, J. Bousquet, and B. Sousa-Pinto) from the Climate Action To Advance HeaLthY Societies in Europe (CATALYSE) Project (Grant No. 101057131).
Dierick, B.J.H., van der Molen, T., Flokstra-de Blok, B.M.J., Muraro, A., Postma, M.J., Kocks, J.W.H., et al. Burden and socioeconomics of asthma, allergic rhinitis, atopic dermatitis and food allergy. Expert Rev Pharmacoecon Outcomes Res 20 (2020), 437–453.
Torrance, G.W., Utility approach to measuring health-related quality of life. J Chronic Dis 40 (1987), 593–603.
Calvert, M.J., Freemantle, N., Use of health-related quality of life in prescribing research. Part 1: why evaluate health-related quality of life?. J Clin Pharm Ther 28 (2003), 513–521.
Feng, Y.S., Kohlmann, T., Janssen, M.F., Buchholz, I., Psychometric properties of the EQ-5D-5L: a systematic review of the literature. Qual Life Res 30 (2021), 647–673.
Whynes, D.K., Correspondence between EQ-5D health state classifications and EQ VAS scores. Health Qual Life Outcomes 6 (2008), 1–9.
Sousa-Pinto, B., Louis, G., Rodrigues, J., Giuliano, A.F.M., Baiardini, I., Braido, F., et al. Impairment of EQ-5D-5L domains according to allergic rhinitis and asthma control: A MASK-air real-world study. J Allergy Clin Immunol Pract 11 (2023), 3742–3751.e9.
Bousquet, J., Anto, J.M., Sousa-Pinto, B., Czarlewski, W., Bedbrook, A., Haahtela, T., et al. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air approach. Clin Transl Allergy, 13, 2023, e12215.
Bousquet, J., Anto, J.M., Bachert, C., Bosnic-Anticevich, S., Erhola, M., Haahtela, T., et al. From ARIA guidelines to the digital transformation of health in rhinitis and asthma multimorbidity. Eur Respir J, 54, 2019, 1901023.
Bousquet, J., Bedbrook, A., Czarlewski, W., Onorato, G.L., Arnavielhe, S., Laune, D., et al. Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clin Transl Allergy, 9, 2019, 16.
Organisation for Economic Co-operation and Development. Integrating care to prevent and manage chronic diseases: best practices in public health. 2023, OECD Publishing, Paris.
TaylorWessing.com. Digital consent around the world. Accessed February 4 2024. https://globaldatahub.taylorwessing.com/article/digital-consent-around-the-world.
Sousa-Pinto, B., Azevedo, L.F., Jutel, M., Agache, I., Canonica, G.W., Czarlewski, W., et al. Development and validation of combined symptom-medication scores for allergic rhinitis. Allergy 77 (2022), 2147–2162.
Sousa-Pinto, B., Jácome, C., Pereira, A.M., Regateiro, F.S., Almeida, R., Czarlewski, W., et al. Development and validation of an electronic daily control score for asthma (e-DASTHMA): a real-world direct patient data study. Lancet Digit Health 5 (2023), e227–e238.
Andrade, L.F., Ludwig, K., Goni, J.M.R., Oppe, M., de Pouvourville, G., A French value set for the EQ-5D-5L. Pharmacoeconomics 38 (2020), 413–425.
Bouckaert, N., Cleemput, I., Devriese, S., Gerkens, S., An EQ-5D-5L value set for Belgium. Pharmacoecon Open 6 (2022), 823–836.
Devlin, N.J., Shah, K.K., Feng, Y., Mulhern, B., van Hout, B., Valuing health-related quality of life: an EQ-5D-5L value set for England. Health Econ 27 (2018), 7–22.
Ferreira, P.L., Antunes, P., Ferreira, L.N., Pereira, L.N., Ramos-Goñi, J.M., A hybrid modelling approach for eliciting health state preferences: the Portuguese EQ-5D-5L value set. Qual Life Res 28 (2019), 3163–3175.
Finch, A.P., Meregaglia, M., Ciani, O., Roudijk, B., Jommi, C., An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Soc Sci Med, 292, 2022, 114519.
Golicki, D., Jakubczyk, M., Niewada, M., Wrona, W., Busschbach, J.J., Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health 13 (2010), 289–297.
Jensen, C.E., Sørensen, S.S., Gudex, C., Jensen, M.B., Pedersen, K.M., Ehlers, L.H., The Danish EQ-5D-5L value set: a hybrid model using cTTO and DCE data. Appl Health Econ Health Policy 19 (2021), 579–591.
Ludwig, K., Graf von der Schulenburg, J.M., Greiner, W., German value set for the EQ-5D-5L. Pharmacoeconomics 36 (2018), 663–674.
Ramos-Goñi, J.M., Craig, B.M., Oppe, M., Ramallo-Fariña, Y., Pinto-Prades, J.L., Luo, N., et al. Handling data quality issues to estimate the Spanish EQ-5D-5L value set using a hybrid interval regression approach. Value Health 21 (2018), 596–604.
Versteegh, M.M., Vermeulen, K.M., Evers, S.M., De Wit, G.A., Prenger, R., Stolk, E.A., Dutch tariff for the five-level version of EQ-5D. Value Health 19 (2016), 343–352.
Leemann, L., Wasserfallen, F., Measuring attitudes–multilevel modeling with post-stratification (MrP). Curini, L., Franzese, R., (eds.) The SAGE Handbook of Research Methods in Political Science and International Relations, 2020, SAGE Publications, California, 371–384.
Bousquet, J., Neukirch, F., Bousquet, P.J., Gehano, P., Klossek, J.M., Le Gal, M., et al. Severity and impairment of allergic rhinitis in patients consulting in primary care. J Allergy Clin Immunol 117 (2006), 158–162.
Chen, H., Gould, M.K., Blanc, P.D., Miller, D.P., Kamath, T.V., Lee, J.H., et al. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol 120 (2007), 396–402.
Devillier, P., Roche, N., Faisy, C., Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine: a comparative review. Clin Pharmacokinet 47 (2008), 217–230.
Moy, M.L., Israel, E., Weiss, S.T., Juniper, E.F., Dubé, L., Drazen, J.M., Clinical predictors of health-related quality of life depend on asthma severity. Am J Respir Crit Care Med 163 (2001), 924–929.
Bousquet, J., Bullinger, M., Fayol, C., Marquis, P., Valentin, B., Burtin, B., Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 94:2 part 1 (1994), 182–188.
Bousquet, J., Knani, J., Dhivert, H., Richard, A., Chicoye, A., Ware, J.E. Jr., et al. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. Am J Respir Crit Care Med 149:2 part 1 (1994), 371–375.
Dick, K., Briggs, A., Brandi, H., Application of a mapping function to estimate utilities for ragweed allergy immunotherapy trials. Pharmacoecon Open 4 (2020), 649–655.
Speth, M.M., Hoehle, L.P., Phillips, K.M., Caradonna, D.S., Gray, S.T., Sedaghat, A.R., Treatment history and association between allergic rhinitis symptoms and quality of life. Ir J Med Sci 188 (2019), 703–710.
Oh, B.C., Lee, J.E., Nam, J.H., Hong, J.Y., Kwon, S.H., Lee, E.K., Health-related quality of life in adult patients with asthma according to asthma control and severity: a systematic review and meta-analysis. Front Pharmacol, 13, 2022, 908837.
Aburuz, S., Gamble, J., Heaney, L.G., Assessment of impairment in health-related quality of life in patients with difficult asthma: psychometric performance of the Asthma Quality of Life Questionnaire. Respirology 12 (2007), 227–233.
Sousa-Pinto, B., Sa-Sousa, A., Vieira, R.J., Amaral, R., Pereira, A.M., Anto, J.M., et al. Cutoff values of MASK-air patient-reported outcome measures. J Allergy Clin Immunol Pract 11 (2023), 1281–1289.e5.
Leynaert, B., Neukirch, C., Liard, R., Bousquet, J., Neukirch, F., Quality of life in allergic rhinitis and asthma. A population-based study of young adults. Am J Respir Crit Care Med 162:4 part 1 (2000), 1391–1396.
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 63:suppl 86 (2008), 8–160.
Bousquet, J., Melen, E., Haahtela, T., Koppelman, G.H., Togias, A., Valenta, R., et al. Rhinitis associated with asthma is distinct from rhinitis alone: the ARIA-MeDALL hypothesis. Allergy 78 (2023), 1169–1203.
Beaudet, A., Clegg, J., Thuresson, P.O., Lloyd, A., McEwan, P., Review of utility values for economic modeling in type 2 diabetes. Value Health 17 (2014), 462–470.
Di Tanna, G.L., Urbich, M., Wirtz, H.S., Potrata, B., Heisen, M., Bennison, C., et al. Health state utilities of patients with heart failure: a systematic literature review. Pharmacoeconomics 39 (2021), 211–229.
Haridoss, M., Bagepally, B.S., Natarajan, M., Health-related quality of life in rheumatoid arthritis: systematic review and meta-analysis of EuroQoL (EQ-5D) utility scores from Asia. Int J Rheum Dis 24 (2021), 314–326.
Kamstra, R.J.M., Boorsma, A., Krone, T., van Stokkum, R.M., Eggink, H.M., Peters, T., et al. Validation of the mobile app version of the EQ-5D-5L quality of life questionnaire against the gold standard paper-based version: randomized crossover study. JMIR Form Res, 6, 2022, e37303.
Devlin, N., Finch, A.P., Parkin, D., Guidance to users of EQ-5D-5L value sets. Devlin, N., Roudijk, B., Ludwig, K., (eds.) Value sets for EQ-5D-5L: a compendium, comparative review & user guide, 2022, Springer, Cham, Switzerland, 213–233.
Leemann, L., Wasserfallen, F., Measuring attitudes–multilevel modeling with post-stratification (MrP). Curini, L., Franzese, R., (eds.) The SAGE handbook of research methods in political science and international relations, 2020, SAGE Publications, California, 371–384.
Statbel. Population par lieu de résidence, nationalité (Belge/non-Belge), état civil, âge et sexe. https://bestat.statbel.fgov.be/bestat/crosstable.xhtml?datasource=65ee413b-3859-4c6f-a847-09b631766fa7. (Accessed 18 May 2023)
Blomme, K., Tomassen, P., Lapeere, H., Huvenne, W., Bonny, M., Acke, F., et al. Prevalence of allergic sensitization versus allergic rhinitis symptoms in an unselected population. Int Arch Allergy Immunol 160 (2013), 200–207.
Van Wilder, L., Charafeddine, R., Beutels, P., Bruyndonckx, R., Cleemput, I., Demarest, S., et al. Belgian population norms for the EQ-5D-5L, 2018. Qual Life Res 31 (2022), 527–537.
Danmarks Statistik. FOLK2: Folketal 1. januar efter køn, alder, herkomst, oprindelsesland og statsborgerskab. https://www.statbank.dk/FOLK2. (Accessed 18 May 2023)
Grønhøj Larsen, C., Gyldenløve, M., Linneberg, A., Allergic rhinitis is often undiagnosed and untreated: results from a general population study of Danish adults. Clin Respir J 7 (2013), 354–358.
Jensen, M.B., Jensen, C.E., Gudex, C., Pedersen, K.M., Sørensen, S.S., Ehlers, L.H., Danish population health measured by the EQ-5D-5L. Scand J Public Health 51 (2021), 241–249.
Institut National de la Statistique et des Études Économiques. Pyramides des âges—Bilan démographique. 2022, 2022 Accessed May 18, 2023. https://www.insee.fr/fr/statistiques/6688661?sommaire=6686521. (Accessed 18 May 2023)
Savouré, M., Bousquet, J., Leynaert, B., Renuy, A., Siroux, V., Goldberg, M., et al. Rhinitis phenotypes and multimorbidities in the general population: the CONSTANCES cohort. Eur Respir J, 61, 2023, 2200943.
Delmas, M.C., Bénézet, L., Ribet, C., Iwatsubo, Y., Provost, D., Varraso, R., et al. Prevalence of asthma among adults in France, data from the Constances cohort study [in French]. Rev Mal Respir 38 (2021), 797–806.
Gautier, L., Azzi, J., Saba, G., Bonnelye, G., de Pouvourville, G., Population norms in France with EQ-5D-5L: health states, value indexes, and VAS. Eur J Health Econ 24 (2023), 1517–1530.
Bundesamt DS. 12411-0006: Bevölkerung: Deutschland, Stichtag, Altersjahre, Nationalität/Geschlecht/Familienstand. Accessed May 18, 2023. https://www-genesis.destatis.de/genesis//online?operation=table&code=12411-0006&bypass=true&levelindex=0&levelid=1682058903033#abreadcrumb.
Langen, U., Schmitz, R., Steppuhn, H., Prevalence of allergic diseases in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1) [in German]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 56 (2013), 698–706.
Grochtdreis, T., Dams, J., König, H.-H., Konnopka, A., Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set. Eur J Health Econ 20 (2019), 933–944.
Instituto Nazionale di Statistica. Popolazione residente al 1° gennaio per fascia di età. Accessed May 18, 2023. https://esploradati.istat.it/databrowser/#/it/dw/categories/IT1,POP,1.0/POP_POPULATION/DCIS_POPRES1.
Cazzoletti, L., Ferrari, M., Olivieri, M., Verlato, G., Antonicelli, L., Bono, R., et al. The gender, age and risk factor distribution differs in self-reported allergic and non-allergic rhinitis: a cross-sectional population-based study. Allergy Asthma Clin Immunol, 11, 2015, 36.
Cazzola, M., Puxeddu, E., Bettoncelli, G., Novelli, L., Segreti, A., Cricelli, C., Calzetta, L., The prevalence of asthma and COPD in Italy: a practice-based study. Respir Med 105 (2011), 386–391.
Meregaglia, M., Malandrini, F., Finch, A.P., Ciani, O., Jommi, C., EQ-5D-5L population norms for Italy. Appl Health Econ Health Policy 21 (2023), 289–303.
Centraal Bureau voor de Statistiek. Bevolking; geslacht, lft, generatie en migr. 1996-2022 achtergrond, 1 jan https://opendata.cbs.nl/statline/#/CBS/nl/dataset/37325/table?dl=6BDCC. (Accessed 18 May 2024)
Dahl, R., Andersen, P.S., Chivato, T., Valovirta, E., de Monchy, J., National prevalence of respiratory allergic disorders. Respir Med 98 (2004), 398–403.
Vanhommerig JWP, M.J.J.C.; Gommer, A.M.; Hendriks, C.; Wijga, A.H.; Hilderink, H.B.M.; Giesbers, H. Astma | Leeftijd en geslacht. Accessed May 18, 2023. https://www.vzinfo.nl/astma/leeftijd-en-geslacht.
Versteegh, M.M., Vermeulen, K.M., Evers, S.M., De Wit, G.A., Prenger, R., Stolk, E.A., Dutch tariff for the five-level version of EQ-5D. Value Health 19 (2016), 343–352.
Komitet Redakcyjny Głównego Urzędu Statystycznego. Rocznik Demograficzny. 2022, Komitet Redakcyjny Głównego Urzędu Statystycznego, Warsaw, Poland.
Kupryś-Lipińska, I., Elgalal, A., Kuna, P., Urban-rural differences in the prevalence of atopic diseases in the general population in Lodz Province (Poland). Postępy Dermatol Alergol 26 (2009), 249–256.
Golicki, D., Niewada, M., EQ-5D-5L Polish population norms. Arch Med Sci 13 (2017), 191–200.
Golicki, D., Niewada, M., General population reference values for 3-level EQ-5D (EQ-5D-3L) questionnaire in Poland. Pol Arch Med Wewn 125 (2015), 18–26.
Instituto Nacional de Estatística. População residente (N.º) por Local de residência (à data dos Censos 2021), Sexo, Grupo etário e Naturalidade. Accessed May 18, 2023. https://www.ine.pt/xportal/xmain?xpid=INE&xpgid=ine_indicadores&contecto=pi&indOcorrCod=0011628&selTab=tab0).
Morais-Almeida, M., Loureiro, C., Todo-Bom, A., Nunes, C., Pereira, C., Delgado, L., et al. Avaliação da prevalência e caracterização da rinite em utentes dos cuidados de saúde primários de Portugal Continental–Estudo ARPA. Rev Port Imunoalergologia 13:suppl 2 (2005), 3–14.
Sa-Sousa, A., Morais-Almeida, M., Azevedo, L.F., Carvalho, R., Jacinto, T., Todo-Bom, A., et al. Prevalence of asthma in Portugal - the Portuguese National Asthma Survey. Clin Transl Allergy, 2, 2012, 15.
Ferreira, P.L., Pereira, L.N., Antunes, P., Ferreira, L.N., EQ-5D-5L Portuguese population norms. Eur J Health Econ 24 (2023), 1411–1420.
Instituto Nacional de Estadística. Población residente por fecha, sexo y edad. Instituto Nacional de Estadística. Accessed May 18, 2023. https://www.ine.es/jaxiT3/Datos.htm?t=31304.
Instituto Nacional de Estadística. Encuesta Europea de Salud en España. 2020 Instituto Nacional de Estadística. Accessed May 18, 2023. https://www.sanidad.gob.es/estadEstudios/estadisticas/EncuestaEuropea/Enc_Eur_Salud_en_Esp_2020_datos.htm. (Accessed 18 May 2023)
Garcia-Gordillo, M.A., Adsuar, J.C., Olivares, P.R., Normative values of EQ-5D-5L: in a Spanish representative population sample from Spanish Health Survey, 2011. Qual Life Res 25 (2016), 1313–1321.
Office for National Statistics (ONS), released 21 December 2022, ONS website, statistical bulletin, Population estimates for the UK, England, Wales, Scotland and Northern Ireland: mid-2021. https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/bulletins/annualmidyearpopulationestimates/mid202. (Accessed 18 May 2023)
Ghouri, N., Hippisley-Cox, J., Newton, J., Sheikh, A., Trends in the epidemiology and prescribing of medication for allergic rhinitis in England. J R Soc Med 101 (2008), 466–472.
Chloe, I.B., Sejal, S., Johanna, F., Debbie, J., Jennifer, K.Q., Changing prevalence of current asthma and inhaled corticosteroid treatment in the UK: population-based cohort 2006–2016. Eur Respir J, 53, 2019, 1802130.
Janssen, M.F., Szende, A., Cabases, J., Ramos-Goñi, J.M., Vilagut, G., König, H.H., Population norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20 countries. Eur J Health Econ 20 (2019), 205–216.
